315 results
Page 5 of 16
8-K
EX-99.2
wep0 rm0bv10c
9 Apr 19
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-99.1
6hbi r8nho07g
9 Apr 19
Entry into a Material Definitive Agreement
4:43pm
PRER14A
9p6uf7cc
18 Mar 19
Preliminary revised proxy
5:24pm
PRE 14A
vujhobnv22nysn1my232
11 Mar 19
Preliminary proxy
5:07pm
8-K
EX-99.1
rr6n5ytawy
7 Feb 19
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity
4:15pm
8-K
EX-99.1
a93dobdr4s5bcde
15 Jan 19
Entry into a Material Definitive Agreement
5:19pm
424B5
9g8n9k5s
15 Jan 19
Prospectus supplement for primary offering
5:14pm
424B5
o06vqbkn2ay lgp9u
14 Jan 19
Prospectus supplement for primary offering
4:41pm
8-K
EX-99.1
kkusk91vrvghj2gom
7 Jan 19
Results of Operations and Financial Condition
8:11am
8-K
EX-99.1
1tpm145j9scqki 3nb
7 Nov 18
Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity
8:16am
8-K
EX-99.1
4vl5bmpm orb1
10 Aug 18
ONPATTROâ„¢ (patisiran) for the Treatment of the Polyneuropathy of Hereditary
3:45pm
8-K
EX-99.1
lszbdfsp fx
2 Aug 18
Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity
8:15am